This post summarises OHE’s activities at this year’s ISPOR Latin America conference in Santiago, September 2015. Topics include policy options for formulary development in middle-income countries, and role of HTA in definition of health benefit plans.
It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those for other therapy areas.
A new OHE Consulting Report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. The potential value of a new medicine is not likely to be fully known at the time of marketing approval. New uses can expand both the therapeutic and financial value of a particular medicine. In a new study, OHE Consulting seeks to describe and quantify such ‘value expansion’ for a cohort of cancer drugs.
OHE Consulting is now offering our clients advice and analytical services on health outcomes and the use of patient-reported outcomes (PRO) data, building on the extensive programme of original research by OHE in this area. The OHE team is recognised internationally for its methodological work on health outcomes measurement, statistical issues in analysis of PRO data, routine health outcomes data in the NHS, and development of new methods for valuing health states.
In July, OHE released projections for medicines spending in the UK NHS for 2012‒2015. We have now completed further projections, also for the ABPI, for each of the four UK nations (England, Northern Ireland, Scotland and Wales).